UA85698C2 - Хинолиновые промежуточные соединения для синтеза ингибиторов рецепторной тирозинкиназы и способ их получения - Google Patents
Хинолиновые промежуточные соединения для синтеза ингибиторов рецепторной тирозинкиназы и способ их полученияInfo
- Publication number
- UA85698C2 UA85698C2 UAA200609099A UAA200609099A UA85698C2 UA 85698 C2 UA85698 C2 UA 85698C2 UA A200609099 A UAA200609099 A UA A200609099A UA A200609099 A UAA200609099 A UA A200609099A UA 85698 C2 UA85698 C2 UA 85698C2
- Authority
- UA
- Ukraine
- Prior art keywords
- tyrosine kinase
- kinase inhibitors
- receptor tyrosine
- synthesis
- intermediates
- Prior art date
Links
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 2
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 239000000543 intermediate Substances 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53732904P | 2004-01-16 | 2004-01-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA85698C2 true UA85698C2 (ru) | 2009-02-25 |
Family
ID=34807094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200609099A UA85698C2 (ru) | 2004-01-16 | 2005-01-14 | Хинолиновые промежуточные соединения для синтеза ингибиторов рецепторной тирозинкиназы и способ их получения |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US7432377B2 (ru) |
| EP (1) | EP1711467A2 (ru) |
| KR (1) | KR20060123545A (ru) |
| CN (1) | CN1930128A (ru) |
| AR (1) | AR047424A1 (ru) |
| AU (1) | AU2005206541A1 (ru) |
| BR (1) | BRPI0520812A2 (ru) |
| CA (1) | CA2553729A1 (ru) |
| CR (1) | CR8530A (ru) |
| EC (1) | ECSP066773A (ru) |
| GT (1) | GT200500008A (ru) |
| MY (1) | MY136959A (ru) |
| NO (1) | NO20063501L (ru) |
| PA (1) | PA8621501A1 (ru) |
| PE (1) | PE20050896A1 (ru) |
| RU (1) | RU2006127414A (ru) |
| SG (1) | SG149817A1 (ru) |
| TW (1) | TW200526219A (ru) |
| UA (1) | UA85698C2 (ru) |
| WO (1) | WO2005070890A2 (ru) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1930128A (zh) * | 2004-01-16 | 2007-03-14 | 惠氏公司 | 受体酪氨酸激酶抑制剂的喹啉中间体及其合成 |
| WO2006127205A2 (en) * | 2005-05-25 | 2006-11-30 | Wyeth | Methods of preparing 3-cyano-quinolines and intermediates made thereby |
| RU2007140957A (ru) * | 2005-05-25 | 2009-06-27 | Вайет (Us) | Способы синтеза производных 6-алкиламинохинолинов |
| CN101203494A (zh) * | 2005-05-25 | 2008-06-18 | 惠氏公司 | 合成经取代3-氰基喹啉和其中间物的方法 |
| TW200808728A (en) * | 2006-05-23 | 2008-02-16 | Wyeth Corp | Method of preparing 4-halogenated quinoline intermediates |
| US8093246B2 (en) * | 2006-12-14 | 2012-01-10 | Lexicon Pharmaceuticals, Inc. | O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| US8063220B2 (en) | 2007-06-22 | 2011-11-22 | Richter Gedeon Nyrt. | Sulfonyl-quinoline derivatives |
| JP2011523646A (ja) | 2008-05-21 | 2011-08-18 | アリアド・ファーマシューティカルズ・インコーポレイテッド | キナーゼ阻害剤としてのリン誘導体 |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| AU2009262068C1 (en) | 2008-06-27 | 2015-07-02 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
| JP5590040B2 (ja) | 2008-11-12 | 2014-09-17 | アリアド・ファーマシューティカルズ・インコーポレイテッド | キナーゼ阻害剤としてのピラジノピラジンおよび誘導体 |
| PH12013500246A1 (en) | 2010-08-10 | 2019-10-11 | Celgene Avilomics Res Inc | Besylate salt of a btk inhibitor |
| JP5956999B2 (ja) | 2010-11-01 | 2016-07-27 | セルジーン アヴィロミクス リサーチ， インコーポレイテッド | ヘテロアリール化合物およびその使用 |
| BR112013010564B1 (pt) | 2010-11-01 | 2021-09-21 | Celgene Car Llc | Compostos heterocíclicos e composições compreendendo os mesmos |
| EP2637502B1 (en) | 2010-11-10 | 2018-01-10 | Celgene CAR LLC | Mutant-selective egfr inhibitors and uses thereof |
| AU2012250517B2 (en) | 2011-05-04 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| JP2014532658A (ja) | 2011-10-28 | 2014-12-08 | セルジーン アヴィロミクス リサーチ， インコーポレイテッド | ブルトン型チロシンキナーゼ疾患または障害を治療する方法 |
| ES2880109T3 (es) | 2012-03-15 | 2021-11-23 | Celgene Car Llc | Formas sólidas de un inhibidor de la cinasa del receptor del factor de crecimiento epidérmico |
| JP6317320B2 (ja) | 2012-03-15 | 2018-04-25 | セルジーン シーエーアール エルエルシー | 上皮成長因子受容体キナーゼ阻害剤の塩 |
| JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物 |
| US9126950B2 (en) | 2012-12-21 | 2015-09-08 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| CN105188371A (zh) | 2013-02-08 | 2015-12-23 | 西建阿维拉米斯研究公司 | Erk抑制剂及其用途 |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
| US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| WO2016025561A1 (en) | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Forms and compositions of an erk inhibitor |
| BR112017003745A2 (pt) | 2014-08-29 | 2017-12-05 | Tes Pharma S R L | inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico |
| CN106535733A (zh) * | 2014-09-01 | 2017-03-22 | 伊莱克斯电器股份公司 | 支撑组件 |
| US20190112317A1 (en) | 2015-10-05 | 2019-04-18 | The Trustees Of Columbia University In The City Of New York | Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies |
| CN105503720B (zh) * | 2015-12-31 | 2018-07-03 | 重庆威鹏药业有限公司 | 来那替尼中间体的制备方法 |
| CN107501175A (zh) * | 2017-07-25 | 2017-12-22 | 广州大学 | 一种喹啉衍生物的合成方法 |
| CN107501174A (zh) * | 2017-07-25 | 2017-12-22 | 广州大学 | 一种喹啉衍生物的合成方法 |
| CN107417612A (zh) * | 2017-07-25 | 2017-12-01 | 广州大学 | 一种喹啉衍生物的合成方法 |
| MX2020010999A (es) | 2018-04-18 | 2021-01-20 | Constellation Pharmaceuticals Inc | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos. |
| EP3797108B1 (en) | 2018-05-21 | 2022-07-20 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| PE20220562A1 (es) | 2019-07-24 | 2022-04-13 | Constellation Pharmaceuticals Inc | Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida |
| KR102713340B1 (ko) * | 2022-11-08 | 2024-10-02 | 경희대학교 산학협력단 | 고리화첨가 반응과 고리축소 반응의 연속 반응을 이용한 피롤로[1,2-a]퀴놀린의 제조방법 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA73073C2 (ru) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Замещенные 3-циан хинолины |
| ES2235331T3 (es) | 1997-05-28 | 2005-07-01 | Aventis Pharmaceuticals Inc | Compuestos quinolina y quinoxalina que inhiben el factor de crecimiento derivado de plaquetas y/o tirosina quinasas p561ck. |
| US6245760B1 (en) | 1997-05-28 | 2001-06-12 | Aventis Pharmaceuticals Products, Inc | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
| US6297258B1 (en) * | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| HU230728B1 (hu) | 1998-09-29 | 2017-12-28 | Wyeth Holdings Llc | Szubsztituált 3-cianokinolinok mint protein tirozin kinázok inhibitorai |
| GB9910577D0 (en) * | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
| EP1294709A2 (en) | 2000-01-28 | 2003-03-26 | AstraZeneca AB | Quinoline derivatives and their use as aurora 2 kinase inhibitors |
| WO2002036570A1 (en) | 2000-11-02 | 2002-05-10 | Astrazeneca Ab | 4-substituted quinolines as antitumor agents |
| UA77200C2 (en) * | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
| WO2003093240A1 (en) * | 2002-04-30 | 2003-11-13 | Yungjin Pharmaceutical Co., Ltd. | Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same |
| CL2004000016A1 (es) * | 2003-01-21 | 2005-04-15 | Wyeth Corp | Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina. |
| US7365203B2 (en) * | 2003-09-15 | 2008-04-29 | Wyeth | Process for the synthesis of 6-amino-4-(3-chloro-4-fluoro-phenylamino)-7-ethoxy-quinoline-3-carbonitrile |
| CN1930128A (zh) * | 2004-01-16 | 2007-03-14 | 惠氏公司 | 受体酪氨酸激酶抑制剂的喹啉中间体及其合成 |
| GB0509224D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of intracellular enzymatic activity |
-
2005
- 2005-01-14 CN CNA2005800077483A patent/CN1930128A/zh active Pending
- 2005-01-14 EP EP05711511A patent/EP1711467A2/en not_active Withdrawn
- 2005-01-14 SG SG200900078-7A patent/SG149817A1/en unknown
- 2005-01-14 WO PCT/US2005/001384 patent/WO2005070890A2/en not_active Ceased
- 2005-01-14 BR BRPI0520812-2A patent/BRPI0520812A2/pt not_active IP Right Cessation
- 2005-01-14 PA PA20058621501A patent/PA8621501A1/es unknown
- 2005-01-14 US US11/036,408 patent/US7432377B2/en not_active Expired - Fee Related
- 2005-01-14 RU RU2006127414/04A patent/RU2006127414A/ru not_active Application Discontinuation
- 2005-01-14 AU AU2005206541A patent/AU2005206541A1/en not_active Withdrawn
- 2005-01-14 UA UAA200609099A patent/UA85698C2/ru unknown
- 2005-01-14 CA CA002553729A patent/CA2553729A1/en not_active Abandoned
- 2005-01-14 GT GT200500008A patent/GT200500008A/es unknown
- 2005-01-14 TW TW094101148A patent/TW200526219A/zh unknown
- 2005-01-14 KR KR1020067016319A patent/KR20060123545A/ko not_active Withdrawn
- 2005-01-15 MY MYPI20050166A patent/MY136959A/en unknown
- 2005-01-17 PE PE2005000069A patent/PE20050896A1/es not_active Application Discontinuation
- 2005-01-17 AR ARP050100169A patent/AR047424A1/es unknown
-
2006
- 2006-07-24 CR CR8530A patent/CR8530A/es not_active Application Discontinuation
- 2006-08-01 NO NO20063501A patent/NO20063501L/no not_active Application Discontinuation
- 2006-08-16 EC EC2006006773A patent/ECSP066773A/es unknown
-
2008
- 2008-08-28 US US12/200,120 patent/US20090030197A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NO20063501L (no) | 2006-09-28 |
| WO2005070890A3 (en) | 2005-11-03 |
| CR8530A (es) | 2008-09-23 |
| MY136959A (en) | 2008-12-31 |
| US7432377B2 (en) | 2008-10-07 |
| WO2005070890A2 (en) | 2005-08-04 |
| BRPI0520812A2 (pt) | 2009-10-06 |
| AU2005206541A1 (en) | 2005-08-04 |
| CA2553729A1 (en) | 2005-08-04 |
| KR20060123545A (ko) | 2006-12-01 |
| US20050159446A1 (en) | 2005-07-21 |
| SG149817A1 (en) | 2009-02-27 |
| TW200526219A (en) | 2005-08-16 |
| EP1711467A2 (en) | 2006-10-18 |
| CN1930128A (zh) | 2007-03-14 |
| RU2006127414A (ru) | 2008-02-27 |
| AR047424A1 (es) | 2006-01-18 |
| ECSP066773A (es) | 2006-11-16 |
| PA8621501A1 (es) | 2005-08-10 |
| GT200500008A (es) | 2005-08-16 |
| PE20050896A1 (es) | 2005-11-14 |
| US20090030197A1 (en) | 2009-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG149817A1 (en) | Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof | |
| HU0400405D0 (en) | Novel compounds | |
| DK1713475T3 (da) | 1,3,5-trisubstituerede 4,5-dihydro-1H-pyrazol-derivater med CB1-antagonistisk aktivitet | |
| MXPA03010207A (es) | Nuevas 4-anilinoquinolin-3-carboxamidas. | |
| WO2004063151A3 (en) | Novel tyrosine kinase inhibitors | |
| TW200621737A (en) | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | |
| SG153811A1 (en) | Quinazolinone derivatives useful as vanilloid antagonists | |
| ATE374190T1 (de) | Tetrahydrochinazolinderivate als cfr-antagonisten | |
| WO2005060959A8 (en) | Pyrazole derivatives and use thereof as orexin receptor antagonists | |
| TNSN07006A1 (en) | Novel heterocyclic compounds | |
| TW200720260A (en) | Prokineticin 1 receptor antagonists | |
| MY139454A (en) | 4-(aminomethyl)-piperidine benzamides as 5ht4-antagonists | |
| WO2006047415A3 (en) | FACTOR Xa COMPOUNDS | |
| PL376896A1 (pl) | Sposoby wytwarzania 5-androstenów podstawionych w pozycji C-7 | |
| TW200628153A (en) | Novel compounds | |
| MX2007007446A (es) | Procesos para la produccion de 4-aminoquinazolinas. | |
| SI1893589T1 (sl) | Substituirani N-benzo(d)izoksazol-3-il-aminski derivati kot inhibitorji mGluR5, serotonin-(5-HT) in noradrenalinskih receptorjev in njihova uporaba za pripravo zdravil | |
| ZA200804858B (en) | Sulfoximine derivatives as p38 map kinase inhibitors | |
| TW200612944A (en) | 4-(2,4-dichloro-5-methoxyphenyl)amino-6-methoxy-7-{[5-(substituted-amino)methyl]-3-furyl}-3-quinolinecarbonitriles as kinase inhibitors | |
| TW200611900A (en) | Process for the preparation of 3-amino-8-(1-piperazinyl)-2H-1-benzopyran-2-one and salts and solvates thereof | |
| MX2007003159A (es) | Derivados piridinicos de indolin-2-ona, prepracion y uso terapeutico de los mismos. | |
| PL1638959T3 (pl) | 4-(Aminometylo)piperydynobenzamidy antagonistyczne względem 5HT4 | |
| DE602004029888D1 (en) | Hydroxycarbonylphenyl substituierte 4-(aminomethyl)-piperidinbenzamide als 5ht4-antagonisten | |
| UA84594C2 (en) | 1,3,5-trisubstituted 4,5-dihydro-1h-pyrazole derivatives as cb1 antagonists |